<DOC>
	<DOCNO>NCT01521936</DOCNO>
	<brief_summary>This partially randomize phase II trial study side effect best way give best dose cholecalciferol treat patient acute myeloid leukemia ( AML ) undergo intensive induction chemotherapy . Cholecalciferol may help improve outcome patient AML undergo intensive chemotherapy</brief_summary>
	<brief_title>Cholecalciferol Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess patient regard change 25 ( OH ) -D3 change supplementation . II . To develop pharmacokinetic model describe time course relationship vitamin D3 ( cholecalciferol ) supplementation drive level 25 ( OH ) -D3 intensive induction chemotherapy . III . To determine safety toxicity vitamin D3 supplementation AML patient undergo intensive induction chemotherapy . SECONDARY OBJECTIVES : I . To explore whether rapid ( load dose vitamin D3 ) normalization 25 ( OH ) -D3 level effect progression free overall survival . II . To explore whether relationship exist pharmacokinetics 25-hydroxy-vitamin D3 white blood cell count . OUTLINE : Patients pretreatment 25 ( OH ) -D3 level 20-31.9 ng/mL ( insufficient level ) randomize 1 2 treatment arm . ARM I : Patients receive load dose cholecalciferol orally ( PO ) day 1 . Patients receive lower-dose cholecalciferol PO begin day 8 . ARM II : Patients receive load dose cholecalciferol PO day 1 . Patients receive higher-dose cholecalciferol PO begin day 8 . Patients pretreatment 25 ( OH ) -D3 level &lt; 20 ng/mL ( deficient level ) receive load dose cholecalciferol PO day 1 8 . Patients receive lower-dose cholecalciferol PO begin day 15 . For patient , treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Pathologic diagnosis newly diagnose AML ( exclude acute promyelocytic leukemia [ APL ] ) Patients undergo intensive induction therapy ( equivalent 7+3 , cytarabine , daunorubicin , etoposide [ ADE ] highdose cytarabine contain regimen ) Subnormal 25 ( OH ) D3 level ( &lt; 32 ng/mL ) Serum calcium = &lt; upper limit normal Demonstrate ability swallow retain oral medication Patients childbearing potential must agree use acceptable contraceptive method ( e.g. , double barrier ) treatment Patient legal representative must understand investigational nature study sign Independent Ethics Committee/Institutional Review Board approve write informed consent form prior receive study related procedure Exclusion Criteria : Patients history nephrocalcinosis Patients receive bisphosphonate treatment within 28 day study entry Pregnant nursing female patient Unwilling unable follow protocol requirement Any condition Investigator 's opinion deem patient unsuitable candidate receive study drug Received investigational agent within 30 day prior enrollment Patients discontinue cimetidine , thiazide diuretic and/or heparin Patients magnesium base antacid offer alternative regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>